当前位置: 首页 > 详情页

Prevention of dementia using mobile phone applications (PRODEMOS): protocol for an international randomised controlled trial.

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE ◇ SSCI

机构: [1]Department of General Practice, Amsterdam UMC Locatie AMC, Amsterdam, The Netherlands [2]Department of Neurology, Amsterdam UMC Locatie AMC, Amsterdam, The Netherlands [3]Beijing Key Laboratory of Clinical Epidemiology, Capital Medical University School of Public Health, Beijing, China [4]Edith Cowan University School of Medical and Health Sciences, Joondalup, Western Australia, Australia [5]INSERM-University of Toulouse UMR1027, Toulouse, France [6]Department of Epidemiology and Public Health, Toulouse University Hospital, Toulouse, France [7]Cambridge Public Health, University of Cambridge, Cambridge, UK [8]Alzheimer Europe, Luxembourg [9]Department of Primary Care and Public Health, Brighton and Sussex Medical School, Brighton, UK [10]Vital Health Software, Ede, The Netherlands [11]Department of Public and Occupational Health, Amsterdam UMC Locatie AMC, Amsterdam, The Netherlands [12]Alzheimer Centre Limburg, School for Mental Health and Neuroscience, Maastricht University Medical Centre, Maastricht, The Netherlands [13]Division of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden [14]School of Public Health, Shandong First Medical University and Shandong Academy of Medical Science, Tai'an, China [15]Beijing Neurosurgical Institute, Beijing, China [16]Center for Cognitive Disorders, Beijing Geriatric Hospital, Beijing, China [17]Department of Geriatrics, The Second Medical Centre and National Clinical Research Centre for Geriatric Diseases, Chinese PLA General Hospital, Beijing, China [18]Fuzhou Comvee Network & Technology Co., Ltd, Fuzhou, China [19]Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China [20]Health Management Institute, The Second Medical Centre and National Clinical Research Centre for Geriatric Diseases, Chinese PLA General Hospital, Beijing, China [21]Centre for Cognitive Neurology, Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China [22]Department of Neurology, Radboud University Donders Institute for Brain, Cognition and Behaviour, Nijmegen, The Netherlands
出处:
ISSN:

摘要:
Profiles of high risk for future dementia are well understood and are likely to concern mostly those in low-income and middle-income countries and people at greater disadvantage in high-income countries. Approximately 30%-40% of dementia cases have been estimated to be attributed to modifiable risk factors, including hypertension, smoking and sedentary lifestyle. Tailored interventions targeting these risk factors can potentially prevent or delay the onset of dementia. Mobile health (mHealth) improves accessibility of such prevention strategies in hard-to-reach populations while at the same time tailoring such approaches. In the current study, we will investigate the effectiveness and implementation of a coach-supported mHealth intervention, targeting dementia risk factors, to reduce dementia risk.The prevention of dementia using mobile phone applications (PRODEMOS) randomised controlled trial will follow an effectiveness-implementation hybrid design, taking place in the UK and China. People are eligible if they are 55-75 years old, of low socioeconomic status (UK) or from the general population (China); have ≥2 dementia risk factors; and own a smartphone. 2400 participants will be randomised to either a coach-supported, interactive mHealth platform, facilitating self-management of dementia risk factors, or a static control platform. The intervention and follow-up period will be 18 months. The primary effectiveness outcome is change in the previously validated Cardiovascular Risk Factors, Ageing and Incidence of Dementia dementia risk score. The main secondary outcomes include improvement of individual risk factors and cost-effectiveness. Implementation outcomes include acceptability, adoption, feasibility and sustainability of the intervention.The PRODEMOS trial is sponsored in the UK by the University of Cambridge and is granted ethical approval by the London-Brighton and Sussex Research Ethics Committee (reference: 20/LO/01440). In China, the trial is approved by the medical ethics committees of Capital Medical University, Beijing Tiantan Hospital, Beijing Geriatric Hospital, Chinese People's Liberation Army General Hospital, Taishan Medical University and Xuanwu Hospital. Results will be published in a peer-reviewed journal.ISRCTN15986016.© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2020]版:
大类 | 3 区 医学
小类 | 3 区 医学:内科
最新[2023]版:
大类 | 3 区 医学
小类 | 3 区 医学:内科
JCR分区:
出版当年[2019]版:
Q2 MEDICINE, GENERAL & INTERNAL
最新[2023]版:
Q1 MEDICINE, GENERAL & INTERNAL

影响因子: 最新[2023版] 最新五年平均 出版当年[2019版] 出版当年五年平均 出版前一年[2018版] 出版后一年[2020版]

第一作者:
第一作者机构: [1]Department of General Practice, Amsterdam UMC Locatie AMC, Amsterdam, The Netherlands
通讯作者:
通讯机构: [11]Department of Public and Occupational Health, Amsterdam UMC Locatie AMC, Amsterdam, The Netherlands [22]Department of Neurology, Radboud University Donders Institute for Brain, Cognition and Behaviour, Nijmegen, The Netherlands
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:16461 今日访问量:0 总访问量:871 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学宣武医院 技术支持:重庆聚合科技有限公司 地址:北京市西城区长椿街45号宣武医院